Read more
Contents include: 'Cytogenetic Abnormalities in Primary and Secondary MDS', 'Genomic Instability Syndromes and Myelodysplasia', 'FAB, WHO, IWG and Beyond', 'Supportive Treatment in Low and High Risk MDS', 'MPD/MDS Overlap Syndromes' and 'Emerging Therapies Including Lenolidamide'.
List of contents
1. Myelodysplastic Syndrome (MDS): How common is it? i.e. epidemiology and risk factors.
E Estey, MD Anderson (soon to move to Fred Hutchinson Cancer
Centre, Seattle).
2. Therapy related myelodysplasia. Predisposing factors and
molecular genetics
J. Pederson-Bjergaard, Denmark.
3. Cytogenetic abnormalities in primary and secondary MDS
D. Haase, Gottingen, Germany
4. The value of SNP and expression profiling in diagnosis and prognosis
Mufti GJ
5. Molecular pathology of 5q-syndrome and 5q- abnormality
Benjamin Ebert, Dana Farber, Boston
6. Genomic instability syndromes and myelodysplasia
Inderjeet Dokal, Barts and The London
7. Animal models of myelodysplasia.
Timothy Graubert, Saint Louis
8. Biological defects of haemopoiesis of low risk MDS
Eva Hellstrom-Lindberg - Sweden
9. Prognostic evaulation of primary MDS
Ulrich Germing, Germany
10. FAB, WHO, IWG and beyond
John Bennett, Rochester
11. Methylation and histone acetylation in the context of MDS
Steve Gore, Johns Hopkins
12. Treatment of MDS with demethylating agents and HDAC inhibitor
Hagop Kantarjian, MD Anderson
13. Supportive treatment in low and high risk MDS
Pierre Fenaux, Paris
14. Allogeneic stem cell transplantation in MDS
Ziyi Lim and Theo De Witte
15. Immune dysregulation and immunosuppressive therapy MDS
Shahram Kordasti, King's College London
16. Aplastic anaemia/MDS overlap syndrome
Neil Young, NIH
17. Clinical and molecular spectrum of Myeloproliferative/Myelodysplastic disorders (MPD/MDS)
Ayalew Tefferi, Mayo Clinic
18. MPD/MDS overlap syndromes
Michael McDevitt
19. Adult and juvenile Chronic Myelomonocytic Leukemia (CMML)
Christine Neimyer and _ Steenma
20. Emerging therapies including Lenolidamide
Alan List, Tampa, Florida
